Description of impact
Research at the University of Aberdeen has directly contributed to the development of the cannabis-based medicine, Sativex®, which was licensed in the UK in 2010 for relieving neuropathic pain and spasticity of multiple sclerosis (MS), removing the need for patients to self-medicate with illegal, "unregulated" cannabis. The research has both enhanced patient welfare and promoted collaboration with industry. Several other countries have also approved Sativex®. Apart from such direct benefits, the research has also increased understanding of the benefits of cannabis-based medicines among the general public, and the main researcher has advised the Home Office on pertinent legislation. Therefore the claimed impact here includes benefits to health and welfare guidelines and on the public understanding of science. In addition industry has invested in research and development and a new product has been commercialised.| Impact status | Impact Completed (Open) |
|---|---|
| Category of impact | Health and Wellbeing |
Documents & Links
Related content
-
Research output
-
Evidence that the plant cannabinoid ¿9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist
Research output: Contribution to journal › Article › peer-review
-
The plant cannabinoid Δ9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice
Research output: Contribution to journal › Article › peer-review
-
Cannabinoids control spasticity and tremor in a multiple sclerosis model
Research output: Contribution to journal › Article
-
Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist
Research output: Contribution to journal › Article › peer-review
-
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin
Research output: Contribution to journal › Literature review
-
The perceived effects of smoked cannabis on patients with multiple sclerosis
Research output: Contribution to journal › Article › peer-review